Where does Five Prime Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Five Prime Therapeutics, Inc. ranks #7,140 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Five Prime Therapeutics, Inc. hold?

Five Prime Therapeutics, Inc. holds 46 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is Five Prime Therapeutics, Inc.'s Innovation Score?

Five Prime Therapeutics, Inc. has an Innovation Score of 45.7 out of 100 (top 23% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Five Prime Therapeutics, Inc. focus on?

Five Prime Therapeutics, Inc.'s top technology area is C07K (Peptides) with 43 patents, ranking #218 of 3,615 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Five Prime Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Five Prime Therapeutics, Inc.'s recent grant velocity is +47% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Five Prime Therapeutics, Inc.'s patents?

Five Prime Therapeutics, Inc.'s patents average 25.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Five Prime Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Five Prime Therapeutics, Inc.

USPTO PatentsView assignee record - 46 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Five ranks #7,140 of 49,997 tracked US assignees by granted-patent volume, with 46 patents across 10 technology areas.

#7,140
of 49,997 US assignees by volume: Top 23%
by Innovation Score (45.7/100): 25.0
avg claims per patent: +47%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7140 · US Corporation #7,140 · 46 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 46 grants
UPPER-Q #7,140/49,997
PHOTO-FINISH DigiCert
CPC-FOCUS C07K · 10 areas
INNOV-PAR 45.7/100
CLAIMS-DENSE 25.0 claims/avg
TYPE-USCORP US Corporation
VEL-UP +47% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: DigiCert, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Five’s 45.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.3 pts (29%) Velocity 6.2 pts (14%) Breadth 11.2 pts (25%) Claim depth 15.0 pts (33%)

Qualcomm Incorporated · highest

85
Asahi Kasei… · near

46
Stant USA · near

46
Five Prime Therapeut… · this assignee

46
Wilson Tool… · near

46
Yeditepe Universitesi · near

46
3D Lighting… · lowest

7

What this shows Five's Innovation Score is 45.7/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Five?

Each dot is one of Five’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Five’s own 25.0 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Five vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Five's grants concentrate

Five Prime Therapeutics, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 93.5% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (6 grants) versus a trough of 1 in 2016. By volume, Five sits between DigiCert, Inc. and Horteve Breeding BV.

Five's three-year grant acceleration

Five Prime Therapeutics, Inc. shows 14 grants in 2022–2024 against only 15 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Digicert

46
Durr Systems

46
Eisenmann

46
Eureka Therapeuti…

46
Foro Energy

46
Gamesa Innovation…

46
GE Jenbacher OG

46
Horteve Breeding…

46
Five Prime Therap… ◀

46

What this shows Five holds 46 patents at rank #7,140, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Five

By rank, the assignees closest to #7,140 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Five's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Five, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Five ranks #218 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Yeditepe Universitesi 46 Wilson Tool International Inc. 46 Stant USA Corp. 46 Asahi Kasei E-materials Corporation 46

Five's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 23% higher than 77% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Five Prime Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	13.0%
2016	1	2.2%
2017	3	6.5%
2018	3	6.5%
2019	4	8.7%
2020	6	13.0%
2021	5	10.9%
2022	5	10.9%
2023	5	10.9%
2024	4	8.7%
2025partial year	4	8.7%

Which technologies does Five Prime Therapeutics, Inc. patent most?

C07K - Peptides 43

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 43

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 11

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

Y02A - Technologies FOR Adaptation TO Climate Change 2

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 1

G02B - Optical Elements, Systems OR Apparatus 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Five Prime Therapeutics, Inc.'s patent record in context - here's where to go next.

Five Prime Therapeutics, Inc.'s lead technology class is C07K (Peptides), 93.5% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #7,140 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Five Prime Therapeutics, Inc. against DigiCert, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.